{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T21:43:29Z","timestamp":1794951809746,"version":"4.9.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004543","name":"CSC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005235","name":"Institute for Advanced Study","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005235","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011102","name":"EU 7th Framework Programme","doi-asserted-by":"publisher","award":["291763"],"award-info":[{"award-number":["291763"]}],"id":[{"id":"10.13039\/100011102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010663","name":"ERC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.antiviral.2018.11.003","type":"journal-article","created":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T22:33:30Z","timestamp":1542062010000},"page":"134-143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["PASylated interferon \u03b1 efficiently suppresses hepatitis B virus and induces anti-HBs seroconversion in HBV-transgenic mice"],"prefix":"10.1016","volume":"161","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8460-3893","authenticated-orcid":false,"given":"Yuchen","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schlapschy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7636-0537","authenticated-orcid":false,"given":"Volker","family":"Morath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Roeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth I.","family":"Vogt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7342-9751","authenticated-orcid":false,"given":"Daniela","family":"Stadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Dittmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Sutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Heikenwalder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Skerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9421-1911","authenticated-orcid":false,"given":"Ulrike","family":"Protzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2018.11.003_bib1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1172\/JCI58847","article-title":"IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome","volume":"122","author":"Belloni","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.antiviral.2018.11.003_bib2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cocis.2017.06.004","article-title":"PASylation\u00ae: a versatile technology to extend drug delivery","volume":"31","author":"Binder","year":"2017","journal-title":"Curr. Opin. Colloid Interface Sci."},{"key":"10.1016\/j.antiviral.2018.11.003_bib3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1099\/0022-1317-59-1-39","article-title":"Involvement of the kidney in catabolism of human leukocyte interferon","volume":"59","author":"Bino","year":"1982","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2018.11.003_bib4","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1089\/jir.1986.6.207","article-title":"Pharmacokinetics and tissue distribution of recombinant human alpha A, D, A\/D(Bgl), and I interferons and mouse alpha-interferon in mice","volume":"6","author":"Bohoslawec","year":"1986","journal-title":"J. Interferon Res."},{"key":"10.1016\/j.antiviral.2018.11.003_bib5","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1517\/17425247.2012.720969","article-title":"Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents","volume":"9","author":"Garay","year":"2012","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.antiviral.2018.11.003_bib6","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/eji.200838311","article-title":"Anti-retroviral effects of type I IFN subtypes in vivo","volume":"39","author":"Gerlach","year":"2009","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.antiviral.2018.11.003_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002868","article-title":"Interferon-alpha subtype 11 activates NK cells and enables control of retroviral infection","volume":"8","author":"Gibbert","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2018.11.003_bib8","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/bph.12010","article-title":"IFN-alpha subtypes: distinct biological activities in anti-viral therapy","volume":"168","author":"Gibbert","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.antiviral.2018.11.003_bib9","doi-asserted-by":"crossref","first-page":"6158","DOI":"10.1128\/JVI.69.10.6158-6169.1995","article-title":"High-level hepatitis B virus replication in transgenic mice","volume":"69","author":"Guidotti","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.11.003_bib10","doi-asserted-by":"crossref","first-page":"29014","DOI":"10.1074\/jbc.M114.602474","article-title":"Enhanced in vivo efficacy of a type I interferon superagonist with extended plasma half-life in a mouse model of multiple sclerosis","volume":"289","author":"Harari","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2018.11.003_bib11","doi-asserted-by":"crossref","first-page":"6558","DOI":"10.1128\/JVI.76.13.6558-6567.2002","article-title":"Differential effect of murine alpha\/beta interferon transgenes on antagonization of herpes simplex virus type 1 replication","volume":"76","author":"Harle","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.11.003_bib12","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/0016-5085(88)90367-8","article-title":"Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B","volume":"95","author":"Hoofnagle","year":"1988","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2018.11.003_bib13","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/biot.200900218","article-title":"PEGylation of therapeutic proteins","volume":"5","author":"Jevsevar","year":"2010","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.antiviral.2018.11.003_bib14","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.cyto.2011.07.019","article-title":"Binding and activity of all human alpha interferon subtypes","volume":"56","author":"Lavoie","year":"2011","journal-title":"Cytokine"},{"key":"10.1016\/j.antiviral.2018.11.003_bib15","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/hep.28025","article-title":"Present and future therapies of hepatitis B: from discovery to cure","volume":"62","author":"Liang","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2018.11.003_bib16","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jhep.2017.05.008","article-title":"Hepatitis B cure: from discovery to regulatory approval","volume":"67","author":"Lok","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2018.11.003_bib17","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.antiviral.2018.11.003_bib18","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B","volume":"351","author":"Marcellin","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.11.003_bib19","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1021\/mp5007147","article-title":"PASylation of murine leptin leads to extended plasma half-life and enhanced in vivo efficacy","volume":"12","author":"Morath","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.antiviral.2018.11.003_bib20","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/284316a0","article-title":"Synthesis in E. coli of a polypeptide with human leukocyte interferon activity","volume":"284","author":"Nagata","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2018.11.003_bib21","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10059-011-1059-6","article-title":"PKR-dependent mechanisms of interferon-alpha for inhibiting hepatitis B virus replication","volume":"32","author":"Park","year":"2011","journal-title":"Mol. Cells"},{"key":"10.1016\/j.antiviral.2018.11.003_bib22","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","author":"Polaris Observatory","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2018.11.003_bib23","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1053\/j.gastro.2007.07.021","article-title":"Antiviral activity and hepatoprotection by heme oxygenase-1 in hepatitis B virus infection","volume":"133","author":"Protzer","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2018.11.003_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005893","article-title":"DNA Polymerase kappa Is a Key Cellular Factor for the Formation of Covalently Closed Circular DNA of Hepatitis B Virus","volume":"12","author":"Qi","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2018.11.003_bib25","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1073\/pnas.0308340100","article-title":"Signal transduction pathways that inhibit hepatitis B virus replication","volume":"101","author":"Robek","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2018.11.003_bib26","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/protein\/gzt023","article-title":"PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins","volume":"26","author":"Schlapschy","year":"2013","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.antiviral.2018.11.003_bib27","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.it.2015.01.002","article-title":"The molecular basis for functional plasticity in type I interferon signaling","volume":"36","author":"Schreiber","year":"2015","journal-title":"Trends Immunol."},{"key":"10.1016\/j.antiviral.2018.11.003_bib28","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1006\/cyto.2001.1000","article-title":"Different activities of type I interferons on hepatitis B virus core promoter regulated transcription","volume":"17","author":"Schulte-Frohlinde","year":"2002","journal-title":"Cytokine"},{"key":"10.1016\/j.antiviral.2018.11.003_bib29","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/s41598-017-00469-1","article-title":"Different antiviral effects of IFNalpha subtypes in a mouse model of HBV infection","volume":"7","author":"Song","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2018.11.003_bib30","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1002\/jps.20125","article-title":"Pharmacokinetic aspects of biotechnology products","volume":"93","author":"Tang","year":"2004","journal-title":"J. Pharmaceut. Sci."},{"key":"10.1016\/j.antiviral.2018.11.003_bib31","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cell.2011.06.048","article-title":"Structural linkage between ligand discrimination and receptor activation by type I interferons","volume":"146","author":"Thomas","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2018.11.003_bib32","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1073\/pnas.252773599","article-title":"Transcriptional and posttranscriptional control of hepatitis B virus gene expression","volume":"100","author":"Uprichard","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2018.11.003_bib33","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.immuni.2006.08.014","article-title":"Complex modulation of cell type-specific signaling in response to type I interferons","volume":"25","author":"van Boxel-Dezaire","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.antiviral.2018.11.003_bib34","doi-asserted-by":"crossref","first-page":"8219","DOI":"10.1128\/JVI.78.15.8219-8228.2004","article-title":"Characterization of the murine alpha interferon gene family","volume":"78","author":"van Pesch","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.11.003_bib35","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0169-409X(02)00027-3","article-title":"Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications","volume":"54","author":"Wang","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.antiviral.2018.11.003_bib36","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-1-62703-481-4_11","article-title":"Bioassay for the measurement of type-I interferon activity","volume":"1031","author":"Widman","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.antiviral.2018.11.003_bib37","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1128\/JVI.74.9.4165-4173.2000","article-title":"Intrahepatic induction of alpha\/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice","volume":"74","author":"Wieland","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.11.003_bib38","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jhep.2016.10.009","article-title":"Human stem cell-derived hepatocytes as a model for hepatitis B virus infection, spreading and virus-host interactions","volume":"66","author":"Xia","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2018.11.003_bib39","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1155\/2017\/4828936","article-title":"Secreted interferon-inducible factors restrict hepatitis B and C virus entry in vitro","volume":"2017","author":"Xia","year":"2017","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.antiviral.2018.11.003_bib40","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1053\/j.gastro.2015.09.026","article-title":"Interferon-gamma and tumor necrosis factor-alpha produced by T cells reduce the HBV persistence form, cccDNA, without cytolysis","volume":"150","author":"Xia","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2018.11.003_bib41","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"Elife"},{"key":"10.1016\/j.antiviral.2018.11.003_bib42","doi-asserted-by":"crossref","first-page":"9200","DOI":"10.1128\/JVI.00933-15","article-title":"The interferon-inducible protein tetherin inhibits hepatitis B virus virion secretion","volume":"89","author":"Yan","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.11.003_bib43","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a021501","article-title":"Antiviral therapies and prospects for a cure of chronic hepatitis B","volume":"5","author":"Zoulim","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.antiviral.2018.11.003_bib44","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.coviro.2016.06.004","article-title":"Current treatments for chronic hepatitis B virus infections","volume":"18","author":"Zoulim","year":"2016","journal-title":"Curr. Opin. Virol."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218304522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218304522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,15]],"date-time":"2020-11-15T03:46:28Z","timestamp":1605411988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354218304522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":44,"alternative-id":["S0166354218304522"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.11.003","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PASylated interferon \u03b1 efficiently suppresses hepatitis B virus and induces anti-HBs seroconversion in HBV-transgenic mice","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}